Search

Search Constraints

You searched for: Author/Creator Hasbini, Ali

Search Results

1. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Issue 10336 (30th April 2022)

2. Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study. Issue 8 (6th June 2022)

3. Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. (January 2020)

4. Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153–163]. (September 2020)

5. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. (July 2018)

6. Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153–163]. (September 2020)

7. Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients. Issue 6 (1st August 2019)

8. Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol. (May 2023)

9. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Issue 6 (June 2016)